1. Home
  2. ACIU vs GAUZ Comparison

ACIU vs GAUZ Comparison

Compare ACIU & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • GAUZ
  • Stock Information
  • Founded
  • ACIU 2003
  • GAUZ 2009
  • Country
  • ACIU Switzerland
  • GAUZ Israel
  • Employees
  • ACIU N/A
  • GAUZ N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • GAUZ Industrial Machinery/Components
  • Sector
  • ACIU Health Care
  • GAUZ Miscellaneous
  • Exchange
  • ACIU Nasdaq
  • GAUZ Nasdaq
  • Market Cap
  • ACIU 189.1M
  • GAUZ 180.1M
  • IPO Year
  • ACIU 2016
  • GAUZ 2024
  • Fundamental
  • Price
  • ACIU $2.02
  • GAUZ $8.61
  • Analyst Decision
  • ACIU Strong Buy
  • GAUZ Strong Buy
  • Analyst Count
  • ACIU 1
  • GAUZ 4
  • Target Price
  • ACIU $12.00
  • GAUZ $15.50
  • AVG Volume (30 Days)
  • ACIU 128.8K
  • GAUZ 25.2K
  • Earning Date
  • ACIU 08-05-2025
  • GAUZ 08-07-2025
  • Dividend Yield
  • ACIU N/A
  • GAUZ N/A
  • EPS Growth
  • ACIU N/A
  • GAUZ N/A
  • EPS
  • ACIU N/A
  • GAUZ N/A
  • Revenue
  • ACIU $32,014,254.00
  • GAUZ $101,165,000.00
  • Revenue This Year
  • ACIU N/A
  • GAUZ $28.49
  • Revenue Next Year
  • ACIU $533.21
  • GAUZ $47.77
  • P/E Ratio
  • ACIU N/A
  • GAUZ N/A
  • Revenue Growth
  • ACIU 91.20
  • GAUZ 18.63
  • 52 Week Low
  • ACIU $1.43
  • GAUZ $6.78
  • 52 Week High
  • ACIU $4.26
  • GAUZ $13.00
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 57.93
  • GAUZ N/A
  • Support Level
  • ACIU $2.01
  • GAUZ N/A
  • Resistance Level
  • ACIU $2.19
  • GAUZ N/A
  • Average True Range (ATR)
  • ACIU 0.14
  • GAUZ 0.00
  • MACD
  • ACIU 0.00
  • GAUZ 0.00
  • Stochastic Oscillator
  • ACIU 60.75
  • GAUZ 0.00

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

Share on Social Networks: